Rebecca E. Jarvis

Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington’s Disease

Roland W. Bürli, Christopher A. Luckhurst, Omar Aziz et al. · Journal of Medicinal Chemistry · 2013 · 149 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors

Christopher A. Luckhurst, Perla Breccia, Andrew J. Stott et al. · ACS Medicinal Chemistry Letters · 2015 · 55 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +10

Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington’s Disease

Andrew J. Stott, Michel Maillard, Vahri Beaumont et al. · ACS Medicinal Chemistry Letters · 2021 · 45 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Compounds activating VCP D1 ATPase enhance both autophagic and proteasomal neurotoxic protein clearance

Lidia Wróbel, Sandra Malmgren Hill, Alvin Djajadikerta et al. · Nature Communications · 2022 · 39 citations · Full text

Life Sciences, Biochemistry, Neuroscience +17

Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington’s Disease Pathology

Natsuko Macabuag, William Esmieu, Perla Breccia et al. · Journal of Medicinal Chemistry · 2022 · 32 citations · Full text

Life Sciences, Genetics, Molecular Biology +17